Healthcare / Drug Manufacturers - GeneralNYSE
$25.63
-0.56 (-2.12%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $9.1B · quality 62.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$146.0B
P/E
19.6x
↓EV/EBITDA
12.5x
↓ROE
9.0%
↑Gross Margin
74.3%
↑Debt/Equity
0.74
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
+1.4%
FCF CAGR
-1.3%
FCF margin
14.5%
FCF / Net income
1.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $62.58B · net income $7.77B · FCF $9.07B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $62.58B | $62.58B | $63.63B | $59.55B | $101.17B | $73.64B | $41.65B | $40.91B | $40.83B | $52.55B | $52.82B | — | — | $51.58B | $54.66B | $61.03B | $65.17B | $49.27B | $48.30B | $48.42B |
| Net Income | $7.77B | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | $9.16B | $16.03B | $11.15B | $21.31B | $7.21B | $6.96B | $9.13B | $22.00B | $14.57B | $10.01B | $8.26B | $8.63B | $8.10B | $8.14B |
| EBITDA | $16.78B | $16.78B | $18.13B | $9.56B | $41.03B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | 1.36 | 1.36 | 1.41 | 0.37 | 5.47 | 3.85 | 1.63 | 2.82 | 1.87 | 3.34 | 1.11 | 1.05 | 1.35 | 3.03 | 1.84 | 1.20 | 0.97 | 1.17 | 1.14 | 1.11 |
| Gross Margin | 74.3% | 74.3% | 71.9% | 58.1% | 66.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 25.2% | 25.2% | 23.3% | 7.1% | 36.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | 12.4% | 12.4% | 12.6% | 3.6% | 31.0% | 29.8% | 22.0% | 39.2% | 27.3% | 40.6% | 13.7% | — | — | 42.7% | 26.7% | 16.4% | 12.7% | 17.5% | 16.8% | 16.8% |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 0.74 | 0.74 | 0.72 | 0.80 | 0.36 | 0.47 | 0.59 | 0.57 | 0.52 | 0.47 | 0.53 | 0.44 | 0.44 | 0.40 | 0.38 | 0.42 | 0.44 | 0.48 | 0.14 | — |
| Current Ratio | 1.25 | 1.25 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $9.07B | $9.07B | $9.84B | $4.79B | $26.03B | $29.87B | $12.18B | $10.54B | $13.84B | $14.85B | $14.37B | $13.29B | $15.88B | $16.48B | $15.42B | $18.58B | $9.94B | $15.38B | $16.54B | $11.47B |
| Returns | ||||||||||||||||||||
| ROE | 9.0% | 9.0% | 9.1% | 2.4% | 32.8% | 28.5% | 14.5% | 25.4% | 17.6% | 29.9% | 12.1% | 10.8% | 12.8% | 28.8% | 17.9% | 12.2% | 9.4% | 9.6% | 14.1% | — |
| Valuation | ||||||||||||||||||||
| P/E | 19.56 | 19.56 | 18.86 | 79.65 | 9.31 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 12.47 | 12.47 | 11.81 | 24.72 | 7.95 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 1.69 | 1.69 | 1.72 | 1.89 | 3.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | -1.6% | -1.6% | 6.8% | -41.1% | — | 76.8% | 1.8% | 0.2% | -22.3% | -0.5% | — | — | — | -5.6% | -10.4% | -6.3% | 32.3% | 2.0% | -0.3% | — |
| EPS Growth | -3.5% | -3.5% | 281.1% | -93.2% | — | 136.2% | -42.2% | 50.8% | -44.0% | 200.9% | 5.4% | -21.8% | -55.5% | 64.4% | 52.8% | 24.5% | -17.1% | 2.5% | 2.6% | — |
| Dividend Yield | 6.6% | 6.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
18.7%
EPS terminal req.
$2.27
Spread vs growth
-22.2%
5Y implied EPS CAGR
15.1%
EPS terminal req.
$2.75
Spread vs growth
-18.7%
10Y implied EPS CAGR
12.5%
EPS terminal req.
$4.43
Spread vs growth
-16.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+15.7%
Start / end P/E
16.7x → 18.8x
EPS bridge
1.41 → 1.36
Residual
-0.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.